Review
doi: 10.1016/S0065-2776(06)90002-9.
Mechanisms of immune evasion by tumors
Affiliations
- PMID: 16730261
- DOI: 10.1016/S0065-2776(06)90002-9
Item in Clipboard
Review
Mechanisms of immune evasion by tumors
Adv Immunol.
2006.
Abstract
In the past decade, basic studies in animal models have begun to elucidate the physiological barriers which impede a successful antitumor immune response. These barriers operate at a number of levels, and involve the tumor, the tumor microenvironment and various components of the innate and adaptive immune systems. In this review, we discuss the multiple mechanisms by which tumors evade an immune response, with an emphasis on clinically relevant strategies to overcome these inhibitory checkpoints.
Similar articles
-
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.Adv Immunol. 2006;90:1-50. doi: 10.1016/S0065-2776(06)90001-7. Adv Immunol. 2006. PMID: 16730260 Review.
-
Basic and tumor immunology: a review.Surg Oncol Clin N Am. 2007 Oct;16(4):711-35, vii. doi: 10.1016/j.soc.2007.08.003. Surg Oncol Clin N Am. 2007. PMID: 18022541 Review.
-
Mechanisms of the self/non-self-survey in the defense against cancer: potential for chemoprevention?Crit Rev Oncol Hematol. 2005 Oct;56(1):5-22. doi: 10.1016/j.critrevonc.2004.12.009. Crit Rev Oncol Hematol. 2005. PMID: 15978831 Review.
-
Inhibitory B7-family molecules in the tumour microenvironment.Nat Rev Immunol. 2008 Jun;8(6):467-77. doi: 10.1038/nri2326. Nat Rev Immunol. 2008. PMID: 18500231 Review.
-
Emerging strategies in regulatory T-cell immunotherapies.Clin Adv Hematol Oncol. 2009 Jan;7(1):1-10; quiz 11-2. Clin Adv Hematol Oncol. 2009. PMID: 19288606 Review.
Cited by
-
Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.Adv Cancer Res. 2015;128:69-93. doi: 10.1016/bs.acr.2015.04.001. Epub 2015 May 12. Adv Cancer Res. 2015. PMID: 26216630 Free PMC article. Review.
-
Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy.PLoS Pathog. 2013;9(5):e1003341. doi: 10.1371/journal.ppat.1003341. Epub 2013 May 9. PLoS Pathog. 2013. PMID: 23671415 Free PMC article.
-
Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.Curr Oncol Rep. 2013 Apr;15(2):98-104. doi: 10.1007/s11912-012-0284-2. Curr Oncol Rep. 2013. PMID: 23263823 Review.
-
Human prostatic acid phosphatase: structure, function and regulation.Int J Mol Sci. 2013 May 21;14(5):10438-64. doi: 10.3390/ijms140510438. Int J Mol Sci. 2013. PMID: 23698773 Free PMC article. Review.
-
A changing landscape in castration-resistant prostate cancer treatment.Front Endocrinol (Lausanne). 2012 Jul 18;3:85. doi: 10.3389/fendo.2012.00085. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 22826702 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
